EP3452056A4 - Nanoparticules de glycogène et de phytoglycogène à titre de composés immunosuppresseurs, compositions et leurs procédés d'utilisation - Google Patents
Nanoparticules de glycogène et de phytoglycogène à titre de composés immunosuppresseurs, compositions et leurs procédés d'utilisation Download PDFInfo
- Publication number
- EP3452056A4 EP3452056A4 EP17792339.8A EP17792339A EP3452056A4 EP 3452056 A4 EP3452056 A4 EP 3452056A4 EP 17792339 A EP17792339 A EP 17792339A EP 3452056 A4 EP3452056 A4 EP 3452056A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- glycogen
- compositions
- methods
- immunosuppressive compounds
- phytoglycogen nanoparticles
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 229920002527 Glycogen Polymers 0.000 title 1
- 229920002387 Phytoglycogen Polymers 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
- BYSGBSNPRWKUQH-UJDJLXLFSA-N glycogen Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@@H](O)[C@@H](O[C@@H]2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)O1 BYSGBSNPRWKUQH-UJDJLXLFSA-N 0.000 title 1
- 229940096919 glycogen Drugs 0.000 title 1
- 230000001506 immunosuppresive effect Effects 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 239000002105 nanoparticle Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
- A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
- A61K47/6931—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer
- A61K47/6939—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer the polymer being a polysaccharide, e.g. starch, chitosan, chitin, cellulose or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5161—Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/0018—Culture media for cell or tissue culture
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0083—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the administration regime
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/90—Polysaccharides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Nanotechnology (AREA)
- Virology (AREA)
- Biotechnology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Optics & Photonics (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Transplantation (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662331662P | 2016-05-04 | 2016-05-04 | |
US201762454424P | 2017-02-03 | 2017-02-03 | |
PCT/CA2017/050545 WO2017190248A1 (fr) | 2016-05-04 | 2017-05-04 | Nanoparticules de glycogène et de phytoglycogène à titre de composés immunosuppresseurs, compositions et leurs procédés d'utilisation |
Publications (2)
Publication Number | Publication Date |
---|---|
EP3452056A1 EP3452056A1 (fr) | 2019-03-13 |
EP3452056A4 true EP3452056A4 (fr) | 2020-03-04 |
Family
ID=60202548
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP17792339.8A Withdrawn EP3452056A4 (fr) | 2016-05-04 | 2017-05-04 | Nanoparticules de glycogène et de phytoglycogène à titre de composés immunosuppresseurs, compositions et leurs procédés d'utilisation |
Country Status (9)
Country | Link |
---|---|
US (1) | US20190117681A1 (fr) |
EP (1) | EP3452056A4 (fr) |
JP (1) | JP2019514963A (fr) |
KR (1) | KR20190005182A (fr) |
CN (1) | CN109310704A (fr) |
AU (1) | AU2017260705A1 (fr) |
BR (1) | BR112018072452A2 (fr) |
CA (1) | CA3022859A1 (fr) |
WO (1) | WO2017190248A1 (fr) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6934767B2 (ja) * | 2017-07-25 | 2021-09-15 | 伯東株式会社 | 超音波伝達効率向上組成物、超音波診断用ゲル組成物及び超音波撮影方法 |
CN109897120B (zh) * | 2019-01-30 | 2020-12-01 | 江南大学 | 一种植物糖原季铵化改性产物的制备方法和产物及其应用 |
WO2020227810A1 (fr) * | 2019-05-10 | 2020-11-19 | Mirexus Biotechnologies Inc. | Compositions de stimulation immunitaire pour espèces d'aquaculture |
CN110616066A (zh) * | 2019-10-14 | 2019-12-27 | 大庆市唯品科技开发有限公司 | 一种改性丙烯酰胺微球冻胶调堵剂 |
CN111518728B (zh) * | 2020-05-11 | 2021-01-22 | 上海海洋大学 | 一种纳米植物糖原乳酸菌复合保护剂、其制备方法及应用 |
WO2023201119A1 (fr) * | 2022-04-15 | 2023-10-19 | University Of Florida Research Foundation, Incorporated | Formulations de phytoglycogène de maïs pour stabiliser des protéines |
CN115028754B (zh) * | 2022-06-30 | 2023-08-11 | 上海市农业科学院 | 硫酸化猴头菌子实体β-葡聚糖、硫酸化β-葡聚糖-壳聚糖纳米颗粒及其制备方法和应用 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060264467A1 (en) * | 2005-05-17 | 2006-11-23 | Benjamin Mugrage | Method for the treatment of Pompe disease using 1-deoxynojirimycin and derivatives |
WO2013135471A1 (fr) * | 2012-03-15 | 2013-09-19 | Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A. | Polymères cationiques à base de glycogène |
WO2017177342A1 (fr) * | 2016-04-14 | 2017-10-19 | Mirexus Biotechnologies Inc. | Compositions anti-infectieuses comprenant des nanoparticules de phytoglycogène |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2231765A2 (fr) * | 2007-12-21 | 2010-09-29 | University Of Guelph | Nanoparticules de polysaccharide |
EP2838564A4 (fr) * | 2012-04-19 | 2015-12-02 | Purdue Research Foundation | Alpha-d-glucanes hautement ramifiés |
JP6541643B2 (ja) * | 2013-04-26 | 2019-07-10 | ミレクサス バイオテクノロジーズ インコーポレイテッド | フィトグリコーゲンナノ粒子及びその製造方法 |
-
2017
- 2017-05-04 KR KR1020187034880A patent/KR20190005182A/ko unknown
- 2017-05-04 AU AU2017260705A patent/AU2017260705A1/en not_active Abandoned
- 2017-05-04 JP JP2018557928A patent/JP2019514963A/ja active Pending
- 2017-05-04 CN CN201780035275.0A patent/CN109310704A/zh active Pending
- 2017-05-04 EP EP17792339.8A patent/EP3452056A4/fr not_active Withdrawn
- 2017-05-04 US US16/098,715 patent/US20190117681A1/en not_active Abandoned
- 2017-05-04 BR BR112018072452-1A patent/BR112018072452A2/pt not_active Application Discontinuation
- 2017-05-04 CA CA3022859A patent/CA3022859A1/fr not_active Abandoned
- 2017-05-04 WO PCT/CA2017/050545 patent/WO2017190248A1/fr unknown
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060264467A1 (en) * | 2005-05-17 | 2006-11-23 | Benjamin Mugrage | Method for the treatment of Pompe disease using 1-deoxynojirimycin and derivatives |
WO2013135471A1 (fr) * | 2012-03-15 | 2013-09-19 | Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A. | Polymères cationiques à base de glycogène |
WO2017177342A1 (fr) * | 2016-04-14 | 2017-10-19 | Mirexus Biotechnologies Inc. | Compositions anti-infectieuses comprenant des nanoparticules de phytoglycogène |
Non-Patent Citations (3)
Title |
---|
JONATHAN D. NICKELS ET AL: "Structure and Hydration of Highly-Branched, Monodisperse Phytoglycogen Nanoparticles", BIOMACROMOLECULES, vol. 17, no. 3, 11 February 2016 (2016-02-11), US, pages 735 - 743, XP055591087, ISSN: 1525-7797, DOI: 10.1021/acs.biomac.5b01393 * |
LIN BI ET AL: "Designing carbohydrate nanoparticles for prolonged efficacy of antimicrobial peptide", JOURNAL OF CONTROLLED RELEASE, ELSEVIER, AMSTERDAM, NL, vol. 150, no. 2, 21 November 2010 (2010-11-21), pages 150 - 156, XP028155807, ISSN: 0168-3659, [retrieved on 20101127], DOI: 10.1016/J.JCONREL.2010.11.024 * |
See also references of WO2017190248A1 * |
Also Published As
Publication number | Publication date |
---|---|
CA3022859A1 (fr) | 2017-11-09 |
KR20190005182A (ko) | 2019-01-15 |
BR112018072452A2 (pt) | 2019-02-19 |
US20190117681A1 (en) | 2019-04-25 |
CN109310704A (zh) | 2019-02-05 |
JP2019514963A (ja) | 2019-06-06 |
EP3452056A1 (fr) | 2019-03-13 |
WO2017190248A1 (fr) | 2017-11-09 |
AU2017260705A1 (en) | 2018-11-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3510157A4 (fr) | Variants de l'endonucléase homing pd1, compositions et procédés d'utilisation | |
EP3458074A4 (fr) | Compositions destinées à l'administration d'arnt sous la forme de nanoparticules et procédé d'utilisation associé | |
EP3500696A4 (fr) | Variants d'endonucléase de homing du récepteur alpha de l'il-10, compositions et méthodes d'utilisation associées | |
EP3452056A4 (fr) | Nanoparticules de glycogène et de phytoglycogène à titre de composés immunosuppresseurs, compositions et leurs procédés d'utilisation | |
EP3337823A4 (fr) | Compositions de support-agent de liaison et leurs procédés de fabrication et d'utilisation | |
EP3221391A4 (fr) | Compositions pouvant gonfler, articles en étant constitués et leurs procédés de production | |
EP3270694A4 (fr) | Entités chimiques, compositions et méthodes particulières | |
EP3497087A4 (fr) | Entités chimiques, compositions et méthodes particulières | |
EP3307071A4 (fr) | Compositions de methylobacterium antifongiques et leurs procédés d'utilisation | |
EP3435956A4 (fr) | Compositions photo-stabilisées et leurs procédés d'utilisation | |
EP3204386A4 (fr) | Composés aminopurine substitués, compositions correspondantes, et procédés de traitement les utilisant | |
EP3186286A4 (fr) | Compositions contenant de la cellulose et leurs procédés de production | |
EP3386927A4 (fr) | Compositions polymères et procédés d'utilisation | |
EP3407976A4 (fr) | Compositions et utilisations d'agents alpha-adrénergiques | |
EP3503879A4 (fr) | Compositions et procédés associés | |
EP3526334A4 (fr) | Variants de l'endonucléase tgfbéta r2, compositions et procédés d'utilisation | |
EP3356470B8 (fr) | Compositions de copolymère de polycarbonate-polysiloxane, objets formés à partir de celles-ci et procédés pour leur fabrication | |
EP3197621A4 (fr) | Compositions à base de titane, leurs procédés de fabrication et leurs utilisations | |
EP3157982A4 (fr) | Compositions de mélange de polymères et procédés de préparation | |
EP3552017A4 (fr) | Composés, compositions et méthodes | |
EP3496768A4 (fr) | Compositions antimicrobiennes et procédés d'utilisation associés. | |
EP3541169A4 (fr) | Compositions de caryophyllène, appareils et procédés | |
EP3183243A4 (fr) | Composés d'organotellure, leurs compositions et méthodes d'utilisation | |
EP3551619A4 (fr) | Compositions comprenant des promédicaments méthylphénidates, procédés de fabrication et d'utilisation de ces compositions | |
EP3522873A4 (fr) | Compositions et méthodes pour le traitement de la xérostomie |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20181115 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
AX | Request for extension of the european patent |
Extension state: BA ME |
|
DAV | Request for validation of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) | ||
RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: GHOSHAL, SHEETIJ Inventor name: DEWITTE-ORR, STEPHANIE Inventor name: KORENEVSKI, ANTON Inventor name: BERTOLO, LISA SUZANNE Inventor name: SPITERI, KATELIN |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20200205 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61K 31/716 20060101AFI20200130BHEP Ipc: A61K 48/00 20060101ALI20200130BHEP Ipc: A61P 37/06 20060101ALI20200130BHEP Ipc: A61K 9/14 20060101ALI20200130BHEP |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN |
|
18W | Application withdrawn |
Effective date: 20200622 |